Claims
- 1. A method for determining mutation load which comprises identifying a somatic cell that contains accumulated levels of p53, amplifying DNA of the p53 gene from such cell and determining the frequency or nature of mutations in the amplified DNA.
- 2. The method of claim 1, in which the somatic cell that is identified also contains altered levels of a protein selected from the group consisting of PCNA and other proteins that are regulated by p53.
- 3. The method of claim 2, wherein the protein is PCNA.
- 4. The method of claim 2, wherein the protein is mdm2 or vEGF.
- 5. The method of claim 1, in which the somatic cell is identified by immunohistochemical staining for p53.
- 6. The method of claim 2, in which the somatic cell is identified by immunohistochemical staining for p53 and a protein selected from the group consisting of PCNA and other proteins that are regulated by p53.
- 7. The method of claim 1 or 2, in which the amplification is conducted in the presence of mouse DNA or bovine serum albumin or both.
- 8. The method of claim 1 or 2, wherein the DNA that is amplified is from exons 5 to 9 of the p53 gene.
- 9. The method of claim 1 or 2, wherein the DNA that is amplified is at least 1 kb in size.
- 10. The method of claim 1 or 2, wherein the DNA that is amplified is at least 2 kb in size.
- 11. The method of claim 1 or 2, in which the amplification is conducted in the presence of mouse DNA having an average size of at least about 20 kb.
- 12. The method of claim 1 or 2, in which the method is performed on a single somatic cell which is obtained by microdissection from a paraffin-embedded tissue section.
- 13. The method of claim 12, in which the tissue section is fixed with ethanol.
- 14. The method of claim 12 in which the tissue section is subjected to steam heating in the presence of EDTA to facilitate unmasking of antigen sites.
- 15. The method of claim 1 or 2, in which the amplification step utilizes two different DNA polymerases.
- 16. The method of claim 15, in which the two DNA polymerases are Platinum Taq DNA polymerase High Fidelity (Taq/GB-D) and Platinum Taq DNA polymerase.
- 17. The method of claim 11, in which amplification comprises use of primers of the sequence
- 18. The method of claim 17, which further comprises use of primers of the sequence
- 19. The method of claim 17, which further comprises use of primers of the sequence
- 20. The method of claim 12, in which the paraffin-embedded tissue section is prepared from a sample that originated from a patient that is at risk for developing a cancerous condition.
- 21. The method of claim 12, in which the paraffin-embedded tissue section is prepared from a sample that originated from a patient that is currently receiving treatment for a present cancer condition.
- 22. The method of claim 21, in the treatment is radiation treatment.
- 23. The method of claim 21, in the treatment is cytotoxic drug treatment.
- 24. The method of claim 21, in the treatment is gene therapy treatment.
- 25. The method of claim 1 or 2, in which the frequency or nature of mutations is determined by sequence analysis which utilizes one or more of
Parent Case Info
[0001] This application claims priority from U.S. Provisional Application No. 60/246,582, filed Nov. 8, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60246582 |
Nov 2000 |
US |